Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
06 Marzo 2024 - 1:00PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for indications in virology and immunology, today announced that
Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara
L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate
in a fireside chat at Leerink Partners Global Biopharma Conference
on March 13, 2024 at 10:40 a.m. ET in Miami, FL.
A live webcast of the event will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of
Enanta’s website at www.enanta.com. A replay of the webcast will be
available following the presentation and will be archived for at
least 30 days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs with an emphasis on indications
in virology and immunology. Enanta’s research and development
programs are currently focused on respiratory syncytial virus (RSV)
and chronic spontaneous urticaria (CSU) and the company has
previously advanced clinical-stage compounds for SARS-CoV-2
(COVID-19) and chronic hepatitis B virus (HBV) infection.
Glecaprevir, a protease inhibitor discovered by Enanta, is part
of one of the leading treatment regimens for curing chronic
hepatitis C virus infection (HCV) and is sold by AbbVie in numerous
countries under the trade names MAVYRET® (U.S.) and MAVIRET®
(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie contribute ongoing funding to Enanta’s
operations. Please visit http://www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240306946767/en/
Media and Investors Jennifer Viera 617-744-3848
jviera@enanta.com
Grafico Azioni Enanta Pharmaceuticals (NASDAQ:ENTA)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Enanta Pharmaceuticals (NASDAQ:ENTA)
Storico
Da Feb 2024 a Feb 2025
